(Q39486283)

English

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

phase I clinical trial

0 references

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

breast cancer surgery

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Janis Gardovskis

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Janusz Jaśkiewicz

3

object named as

Janusz Jaskiewicz

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Nigel Bundred

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Janis Eglitis

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Viktor Paramonov

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Peter McCormack

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Helen Swaisland

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Maria Cavallin

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Tony Parry

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

James Carmichael

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

J Michael Dixon

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

13 January 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

949-958

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

https://scigraph.springernature.com/pub.10.1007/s10637-012-9922-7

0 references

PARP inhibition: PARP1 and beyond

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Synthetic lethality: general principles, utility and detection using genetic screens in human cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Base Excision Repair and its Role in Maintaining Genome Stability

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Poly(adenosine diphosphoribose) polymerase in peripheral blood leukocytes from normal donors and patients with malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9922-7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39486283&oldid=2143930888"